ArticleOncotarget2017

Biological and clinical evidence for somatic mutations in BRCA1 and BRCA2 as predictive markers for olaparib response in high-grade serous ovarian cancers in the maintenance setting.

Brian A Dougherty et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.